In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A FISH on the Line

Executive Summary

Vysis Inc., which is attempting to penetrate the market with its FISH DNA probe technology, got a boost in May when it announced a collaboration with Genentech Inc. to couple the FISH breast cancer test with Genentech's drug, Herceptin. Vysis hopes the deal will showcase FISH technology and attract other drug developers as partners. Genentech, meanwhile, needs such a test to better screen one class of patients to determine their suitability for treatment with Herceptin, in light of controversy over how accurate the existing IHC diagnostic test is in determining their Her2 status.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts